Precision medicine is an emerging approach to preventive health and for the treatment of disease. The approach allows doctors and physicians to study the individual response to a therapy. The approach studies the individual profile at a genetic level along with their lifestyle and environment. In January 2015, Precision Medicine Initiative (PMI) was announced to extend precision medicine to all diseases with more than one million volunteers. All of The Unified Shared Services Management, a data-driven enterprise supported research at the intersection of environment, lifestyle and genetics to treat disease and prolong health. Targeted cancer therapy, use of combination therapies and knowledge of drug resistance were some of the short term goals. While the long-term goal was to create a cohort of 1 million American volunteers to share genetic data, lifestyle information, biological samples which would be linked to the electronic health record. This would advance pharmacogenomics and lay a scientific foundation for precision medicine for many diseases.
Global Precision Medicine Market Value and Forecast
The global precision medicine market, estimated to be worth around US$ 56 Bn by 2016 end, is expected to expand at an approximate CAGR of 14% over the forecast period of 2016–2024. North America accounted for largest market share and the net average net worth of the market was close to US$ 19 Bn in 2015 and is expected to expand at a CAGR of more than 13.5 % over the forecast period.
Global Precision Medicine Market Dynamics
Factors such as the increasing approval of drug along with its companion diagnostic assay, cost- effective profiling of DNA, increasing incidence rate of cancer and rise of data-driven healthcare are some of the reasons leading to the growth of the precision medicine market. Moreover, the increasing use of “multi-omics” in research along with the penetration of high-throughput sequencing platforms is also shaping up the precision medicine scenario. The number of targeted molecules in pipeline for a specific application has been exponentially growing specifically in oncology.
The current escalating price of drug discovery along with increasing regulatory requirements has increased the demand for an individualized product. The development of companion diagnostics appears to offer a set of tools as well as relevant clinical and biological information to address various pharmaceutical companies. Industry players are now patenting a molecule along with its companion diagnostics to achieve a competitive edge, profit margin and more usage. With the available companion diagnostics, both patient and physicians are assured of the therapy effectiveness.
Global Precision Medicine Market Segmentation Forecast
Based on application, the market has been segmented into multiple layers. Oncology, Immunology, Neurology, Cardiology, Infectious disease and others are some of the crucial streams of application segment. Oncology segment accounts for a significant share in terms of revenue of the total precision medicine market; however, immunology segment is anticipated to witness an impressive CAGR over the forecast period.
Global Precision Medicine Market Forecast by Region
Geographically, North America is leading the precision medicine market. The massive investment in the field of precision medicine in US will trigger the growth of the market within the assessment period. Though the funding is for oncology targeted therapy, the research would gradually expand to other applications. North America is at the forefront as far as the acceptance and utilization of precision medicine is concerned. As economically developing regions such as Asia-Pacific are still behind the developed countries, this region has huge potential for market growth, and this region will showcase significant hike by the end of the forecast period.
Key Players Operating in the Global Precision Medicine Market
Some of the players in the global precision medicine market are, F Hoffmann-La Roche AG, Illumina, Inc., Thermo Fisher Scientific Inc., QIAGEN, Quest Diagnostics, Laboratory Corporation of America Holdings, Novartis AG, AstraZeneca, Bristol-Myers Squibb and Eli Lilly And Company. The companies are trying to increase their product pipeline by filing new molecule application or by extending the application of the existing molecule.
Other strategies such as merger and acquisitions, industry academia collaboration to bring in more commercialized molecule or sequencing techniques will also impact the present market trends. The report also identifies company-specific strategies related to product development, market consolidation initiatives and analysis of their specific strengths, weaknesses, opportunities and threats.
Our reports have been used by over 10K customers, including:
2019 Global Nucleic Acid Testing/NAT Market: Supplier Shares by Country, Facilities, Test Volumes, and Sales Forecasts by Country This report provides: - Worldwide overview of the molecular diagnostics market, including France, Germany, Italy, Japan, Spain, UK and USA. - Estimates of facilities performing...
The global DNA next generation sequencing market is expected to reach US$ 22,716.9 Mn in 2025 from US$ 4,898.5 Mn in 2017. The market is estimated to grow with a CAGR of 21.7% from 2018-2025. The growth of the DNA next generation sequencing market is attributed to the declining prices of sequencing services as well as various technological...
2019-2023 US Flow Cytometry Reagent and Instrument Market: Supplier Shares and Strategies, Country Test Volume and Sales Segment Forecasts, Emerging Technologies, Instrumentation and Opportunities This report contains 147 pages, 17 tables and presents a comprehensive analysis of the US flow cytometry market, including:Major...
2019-2023 Germany Hospital Infectious Disease Testing Market: Supplier Shares and Strategies, Volume and Sales Forecasts, Emerging Technologies, Instrumentation and Opportunities This new report contains 897 pages, 74 tables, and presents a comprehensive analysis of the German hospital infectious disease testing...
The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer testing market is promising to be an exciting,...
KEY FINDINGS The global cancer biomarker market is expected to grow at a CAGR of 11.32% between the years 2019-2027. Some of the important drivers for the global cancer biomarker market include encouragement by the FDA for biomarker development, the adoption of western lifestyles in developing countries, heavy investments...
2019-2023 Japan Molecular Diagnostic Analyzers and Reagents: Market Share Analysis, Country Segment Forecasts, Competitive Intelligence, Technology Trends, Opportunities for Suppliers This new 1,126-page report contains 56 tables, and presents a comprehensive analysis of the Japanese molecular diagnostics market, including:...
2018 Emerging Virology and Bacteriology Diagnostic Technologies, Country Market Shares, Strategic Profiles of Leading Suppliers This 155-page report provides detailed analyses of current and emerging technologies, and their potential applications for the infectious disease testing market, including molecular diagnostics,...
Introduction Active pharmaceutical ingredient (API) is a biologically active pharmaceutical drug. API can be obtained by a synthetic process or from natural sources. The increasing occurrence of chronic diseases, rising acceptance, and uptake of pharmaceuticals, growth in abbreviated new drug applications (ANDA), and...
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.